Successful allogeneic stem cell transplantation in second chronic-phase CML induced by the tyrosine kinase inhibitor nilotinib (AMN107) after blast crisis under imatinib [1]

Bone Marrow Transplantation

Volumn 40, Issue 1, 2007, Pages 83-84

  Menzel, H ^a   von Bubnoff, N ^a   Hochhaus, A ^b   Haferlach, C ^c   Peschel, C ^a   Duyster, J ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c MLL MUNICH LEUKEMIA LABORATORY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; BCR ABL PROTEIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEFIBROTIDE; IMATINIB; METHOTREXATE; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ANEMIA; BACTERIAL INFECTION; BLAST CELL CRISIS; CASE REPORT; CHROMOSOME DUPLICATION; CHRONIC MYELOID LEUKEMIA; CYTOMEGALOVIRUS INFECTION; DRUG DOSE INCREASE; GENE AMPLIFICATION; GRAFT VERSUS HOST REACTION; HUMAN; LETTER; LEUKEMIA REMISSION; MALE; MYCOSIS; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; THROMBOCYTOPENIA; VEIN OCCLUSION; VIRUS INFECTION; WHOLE BODY RADIATION;

ANTINEOPLASTIC AGENTS; BLAST CRISIS; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; NEOPLASM STAGING; PIPERAZINES; PYRIMIDINES; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 34347386254     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705683     Document Type: Letter

References (12)

1. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A et al. Risk assessment forpatients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998; 352: 1087-1092.
2. Guilhot F. Sustained Durability of Responses Plus High Rates of Cytogenetic Responses Result in Long-Term Benefit for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Treated with Imatinib (IM) Therapy: Update from the IRIS Study. American Society of Hematology: San Diego, CA, 2004, p 10a.
3. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423-1432.
4. Gratwohl A. Does early stem-cell transplantation have a role in chronic myeloid leukaemia? For the proposal. Lancet Oncol 2005; 6: 721-722.
5. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM et al. Activity of a specific inhibitorof the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-1042.
6. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood 2002; 99: 1928-1937.
7. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530-3539.
8. Ottmann OG, Druker BJ, Sawyers CL, Goldman JM, Reiffers J, SilverR T et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002; 100: 1965-1971.
9. Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: Transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006; 91: 513-521.
10. Sacchi S, Kantarjian HM, O'Brien S, Cortes J, Rios MB, Giles FJ et al. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer 1999; 86: 2632-2641.
11. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354: 2542-2551.
12. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531-2541.